The risk predictive values of UK-PBC and GLOBE scoring system in Chinese patients with primary biliary cholangitis

the additional effect of anti-gp210

F. Yang, Y. Yang, Q. Wang, Z. Wang, Q. Miao, X. Xiao, Y. Wei, Z. Bian, L. Sheng, X. Chen, D. Qiu, J. Fang, R. Tang, M. Eric Gershwin, X. Ma

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Background: Adequate risk stratification is critical for the management of the patients with primary biliary cholangitis (PBC). The UK-PBC and GLOBE scoring systems for prognosis of PBC have been proposed recently, but have not been validated in Asian population. Aim: To validate the UK-PBC and GLOBE scoring systems in Chinese patients for prognosis of PBC. To clarify the role of anti-gp210 as a biomarker, and to investigate whether anti-gp210 could affect the prognostic values of UK-PBC and GLOBE scoring systems. Methods: We retrospectively analysed 276 patients with PBC evaluated between September 2004 and May 2016, including 133 anti-gp210+ and 143 anti-gp210− patients. Results: The 5-year adverse outcome-free survivals of anti-gp210+ vs. anti-gp210− patients were 70% and 85%, respectively (P = 0.005). Cirrhosis (P = 0.001), albumin level ≤40 g/L (P = 0.011) and platelet count ≤153 × 109 (P < 0.001) had a superimposition effect on anti-gp210 antibody as a risk factor. Furthermore, long-term prognoses were evaluated using the UK-PBC and GLOBE scores. For UK-PBC scoring system, the area under receiver operating characteristic curve (AUROC) was 0.924 for all patients with PBC (n = 223), 0.940 for anti-gp210+ patients (n = 110) and 0.888 for anti-gp210− patients (n = 113). For GLOBE scoring system, the area under receiver operating characteristic curve was 0.901 for all patients with PBC (n = 223), 0.924 for anti-gp210+ patients (n = 110) and 0.848 for anti-gp210− patients (n = 113). UK-PBC score >0.0578 (P < 0.001, HR: 32.736, 95% CI: 11.368–94.267) and GLOBE score <0.850 (P < 0.001, HR: 18.763, 95% CI: 7.968–44.180) were associated with poorer outcomes in the whole cohort. Conclusions: The UK-PBC and GLOBE scoring systems were good 5-year prognostic predictors in Chinese patients with PBC, especially in anti-gp210+ patients. As a biomarker, anti-gp210 antibody was associated with a more severe cholestatic manifestation and a worse long-term prognosis. The anti-gp210 antibody could be added to further optimise the UK-PBC and GLOBE scoring systems.

Original languageEnglish (US)
Pages (from-to)733-743
Number of pages11
JournalAlimentary Pharmacology and Therapeutics
Volume45
Issue number5
DOIs
StatePublished - Mar 1 2017

Fingerprint

Cholangitis
Anti-Idiotypic Antibodies
Biomarkers
Platelet Count
Albumins
Fibrosis

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

The risk predictive values of UK-PBC and GLOBE scoring system in Chinese patients with primary biliary cholangitis : the additional effect of anti-gp210. / Yang, F.; Yang, Y.; Wang, Q.; Wang, Z.; Miao, Q.; Xiao, X.; Wei, Y.; Bian, Z.; Sheng, L.; Chen, X.; Qiu, D.; Fang, J.; Tang, R.; Gershwin, M. Eric; Ma, X.

In: Alimentary Pharmacology and Therapeutics, Vol. 45, No. 5, 01.03.2017, p. 733-743.

Research output: Contribution to journalArticle

Yang, F, Yang, Y, Wang, Q, Wang, Z, Miao, Q, Xiao, X, Wei, Y, Bian, Z, Sheng, L, Chen, X, Qiu, D, Fang, J, Tang, R, Gershwin, ME & Ma, X 2017, 'The risk predictive values of UK-PBC and GLOBE scoring system in Chinese patients with primary biliary cholangitis: the additional effect of anti-gp210', Alimentary Pharmacology and Therapeutics, vol. 45, no. 5, pp. 733-743. https://doi.org/10.1111/apt.13927
Yang, F. ; Yang, Y. ; Wang, Q. ; Wang, Z. ; Miao, Q. ; Xiao, X. ; Wei, Y. ; Bian, Z. ; Sheng, L. ; Chen, X. ; Qiu, D. ; Fang, J. ; Tang, R. ; Gershwin, M. Eric ; Ma, X. / The risk predictive values of UK-PBC and GLOBE scoring system in Chinese patients with primary biliary cholangitis : the additional effect of anti-gp210. In: Alimentary Pharmacology and Therapeutics. 2017 ; Vol. 45, No. 5. pp. 733-743.
@article{42e15518cc1b4af1a0868cac167ef88e,
title = "The risk predictive values of UK-PBC and GLOBE scoring system in Chinese patients with primary biliary cholangitis: the additional effect of anti-gp210",
abstract = "Background: Adequate risk stratification is critical for the management of the patients with primary biliary cholangitis (PBC). The UK-PBC and GLOBE scoring systems for prognosis of PBC have been proposed recently, but have not been validated in Asian population. Aim: To validate the UK-PBC and GLOBE scoring systems in Chinese patients for prognosis of PBC. To clarify the role of anti-gp210 as a biomarker, and to investigate whether anti-gp210 could affect the prognostic values of UK-PBC and GLOBE scoring systems. Methods: We retrospectively analysed 276 patients with PBC evaluated between September 2004 and May 2016, including 133 anti-gp210+ and 143 anti-gp210− patients. Results: The 5-year adverse outcome-free survivals of anti-gp210+ vs. anti-gp210− patients were 70{\%} and 85{\%}, respectively (P = 0.005). Cirrhosis (P = 0.001), albumin level ≤40 g/L (P = 0.011) and platelet count ≤153 × 109 (P < 0.001) had a superimposition effect on anti-gp210 antibody as a risk factor. Furthermore, long-term prognoses were evaluated using the UK-PBC and GLOBE scores. For UK-PBC scoring system, the area under receiver operating characteristic curve (AUROC) was 0.924 for all patients with PBC (n = 223), 0.940 for anti-gp210+ patients (n = 110) and 0.888 for anti-gp210− patients (n = 113). For GLOBE scoring system, the area under receiver operating characteristic curve was 0.901 for all patients with PBC (n = 223), 0.924 for anti-gp210+ patients (n = 110) and 0.848 for anti-gp210− patients (n = 113). UK-PBC score >0.0578 (P < 0.001, HR: 32.736, 95{\%} CI: 11.368–94.267) and GLOBE score <0.850 (P < 0.001, HR: 18.763, 95{\%} CI: 7.968–44.180) were associated with poorer outcomes in the whole cohort. Conclusions: The UK-PBC and GLOBE scoring systems were good 5-year prognostic predictors in Chinese patients with PBC, especially in anti-gp210+ patients. As a biomarker, anti-gp210 antibody was associated with a more severe cholestatic manifestation and a worse long-term prognosis. The anti-gp210 antibody could be added to further optimise the UK-PBC and GLOBE scoring systems.",
author = "F. Yang and Y. Yang and Q. Wang and Z. Wang and Q. Miao and X. Xiao and Y. Wei and Z. Bian and L. Sheng and X. Chen and D. Qiu and J. Fang and R. Tang and Gershwin, {M. Eric} and X. Ma",
year = "2017",
month = "3",
day = "1",
doi = "10.1111/apt.13927",
language = "English (US)",
volume = "45",
pages = "733--743",
journal = "Alimentary Pharmacology and Therapeutics",
issn = "0269-2813",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - The risk predictive values of UK-PBC and GLOBE scoring system in Chinese patients with primary biliary cholangitis

T2 - the additional effect of anti-gp210

AU - Yang, F.

AU - Yang, Y.

AU - Wang, Q.

AU - Wang, Z.

AU - Miao, Q.

AU - Xiao, X.

AU - Wei, Y.

AU - Bian, Z.

AU - Sheng, L.

AU - Chen, X.

AU - Qiu, D.

AU - Fang, J.

AU - Tang, R.

AU - Gershwin, M. Eric

AU - Ma, X.

PY - 2017/3/1

Y1 - 2017/3/1

N2 - Background: Adequate risk stratification is critical for the management of the patients with primary biliary cholangitis (PBC). The UK-PBC and GLOBE scoring systems for prognosis of PBC have been proposed recently, but have not been validated in Asian population. Aim: To validate the UK-PBC and GLOBE scoring systems in Chinese patients for prognosis of PBC. To clarify the role of anti-gp210 as a biomarker, and to investigate whether anti-gp210 could affect the prognostic values of UK-PBC and GLOBE scoring systems. Methods: We retrospectively analysed 276 patients with PBC evaluated between September 2004 and May 2016, including 133 anti-gp210+ and 143 anti-gp210− patients. Results: The 5-year adverse outcome-free survivals of anti-gp210+ vs. anti-gp210− patients were 70% and 85%, respectively (P = 0.005). Cirrhosis (P = 0.001), albumin level ≤40 g/L (P = 0.011) and platelet count ≤153 × 109 (P < 0.001) had a superimposition effect on anti-gp210 antibody as a risk factor. Furthermore, long-term prognoses were evaluated using the UK-PBC and GLOBE scores. For UK-PBC scoring system, the area under receiver operating characteristic curve (AUROC) was 0.924 for all patients with PBC (n = 223), 0.940 for anti-gp210+ patients (n = 110) and 0.888 for anti-gp210− patients (n = 113). For GLOBE scoring system, the area under receiver operating characteristic curve was 0.901 for all patients with PBC (n = 223), 0.924 for anti-gp210+ patients (n = 110) and 0.848 for anti-gp210− patients (n = 113). UK-PBC score >0.0578 (P < 0.001, HR: 32.736, 95% CI: 11.368–94.267) and GLOBE score <0.850 (P < 0.001, HR: 18.763, 95% CI: 7.968–44.180) were associated with poorer outcomes in the whole cohort. Conclusions: The UK-PBC and GLOBE scoring systems were good 5-year prognostic predictors in Chinese patients with PBC, especially in anti-gp210+ patients. As a biomarker, anti-gp210 antibody was associated with a more severe cholestatic manifestation and a worse long-term prognosis. The anti-gp210 antibody could be added to further optimise the UK-PBC and GLOBE scoring systems.

AB - Background: Adequate risk stratification is critical for the management of the patients with primary biliary cholangitis (PBC). The UK-PBC and GLOBE scoring systems for prognosis of PBC have been proposed recently, but have not been validated in Asian population. Aim: To validate the UK-PBC and GLOBE scoring systems in Chinese patients for prognosis of PBC. To clarify the role of anti-gp210 as a biomarker, and to investigate whether anti-gp210 could affect the prognostic values of UK-PBC and GLOBE scoring systems. Methods: We retrospectively analysed 276 patients with PBC evaluated between September 2004 and May 2016, including 133 anti-gp210+ and 143 anti-gp210− patients. Results: The 5-year adverse outcome-free survivals of anti-gp210+ vs. anti-gp210− patients were 70% and 85%, respectively (P = 0.005). Cirrhosis (P = 0.001), albumin level ≤40 g/L (P = 0.011) and platelet count ≤153 × 109 (P < 0.001) had a superimposition effect on anti-gp210 antibody as a risk factor. Furthermore, long-term prognoses were evaluated using the UK-PBC and GLOBE scores. For UK-PBC scoring system, the area under receiver operating characteristic curve (AUROC) was 0.924 for all patients with PBC (n = 223), 0.940 for anti-gp210+ patients (n = 110) and 0.888 for anti-gp210− patients (n = 113). For GLOBE scoring system, the area under receiver operating characteristic curve was 0.901 for all patients with PBC (n = 223), 0.924 for anti-gp210+ patients (n = 110) and 0.848 for anti-gp210− patients (n = 113). UK-PBC score >0.0578 (P < 0.001, HR: 32.736, 95% CI: 11.368–94.267) and GLOBE score <0.850 (P < 0.001, HR: 18.763, 95% CI: 7.968–44.180) were associated with poorer outcomes in the whole cohort. Conclusions: The UK-PBC and GLOBE scoring systems were good 5-year prognostic predictors in Chinese patients with PBC, especially in anti-gp210+ patients. As a biomarker, anti-gp210 antibody was associated with a more severe cholestatic manifestation and a worse long-term prognosis. The anti-gp210 antibody could be added to further optimise the UK-PBC and GLOBE scoring systems.

UR - http://www.scopus.com/inward/record.url?scp=85009760514&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85009760514&partnerID=8YFLogxK

U2 - 10.1111/apt.13927

DO - 10.1111/apt.13927

M3 - Article

VL - 45

SP - 733

EP - 743

JO - Alimentary Pharmacology and Therapeutics

JF - Alimentary Pharmacology and Therapeutics

SN - 0269-2813

IS - 5

ER -